Article

marketwatch.com on 2020-12-14 13:56

CureVac starts Phase 3 clinical trial of its COVID-19 vaccine candidate

Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America

Related news